Rakovina Therapeutics Inc. announced the expansion of two research collaborations to align with its recently announced collaboration with the Deep Docking AI Drug Discovery Platform. On March 27, 2024, the Company announced an agreement granting Rakovina Therapeutics exclusive access to the proprietary Deep Docking AI platform for DNA-damage response targets. Using the Deep Docking AI platform, the Company is analyzing billions of molecular structures to evaluate their potential as targeted cancer drugs.

To support these drug development efforts, the Company has expanded a collaboration with Pharma Inventor Inc., a British Columbia-based chemistry R&D and analytical services company serving pharmaceutical and biotech industries, as well as research institutes and academic research groups across North America. Pharma Inventor has agreed to provide medicinal chemistry support to rapidly synthesize novel lead drug candidates identified by the Deep Docking AI platform for further validation by the Company. Rakovina Therapeutics will own all rights to novel molecules developed through the collaboration.

The Company has also extended and expanded its collaborative research agreement with the University of British Columbia (UBC). Rakovina Therapeutics? established lead optimization research infrastructure at the University?s Vancouver Prostate Center will provide rapid validation of novel drug candidates identified through the Deep Docking AI platform.